Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-12-02 am EST
225.10 SEK   -0.71%
11/21Sobi - Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB ahead of the Annual General Meeting in 2023
AQ
11/18Vaccines and drugs in the pipeline for RSV
RE
11/18Swedish Orphan Biovitrum Proposes New Chair for May 2023 Election
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

09/30/2022 | 02:01am EST

As per 30 September 2022, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 309,804,782 shares. All shares are common shares. The total number of votes is 309,804,782. The increase in the number of shares and votes results from an issue of 2,690,287 class C shares. The class C shares have been issued for the purpose of ensuring fulfilment of commitments under employee incentive programmes and have by virtue of the conversion clause in the articles of association been converted to common shares. As per 30 September 2022 the company holds 13,813,835 common shares.

 

Sobi®

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

 

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

 

This information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08:00 CEST on 30 September 2022.

Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00     www.sobi.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/new-number-of-shares-and-votes-in-swedish-orphan-biovitrum-ab--publ-,c3639365

https://mb.cision.com/Main/14266/3639365/1632600.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
11/21Sobi - Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitr..
AQ
11/18Vaccines and drugs in the pipeline for RSV
RE
11/18Swedish Orphan Biovitrum Proposes New Chair for May 2023 Election
MT
11/18Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB (..
AQ
11/10Sobi Obtains US FDA Authorization for Kineret Use in Treatment of COVID-19-Related Pneu..
MT
11/10U.S. health regulator authorizes Sobi's COVID drug
RE
11/10U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET« (anak..
AQ
11/10Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announc..
CI
11/04Sanofi, Astra win EU approval for prevention of infant RSV
RE
11/01Swedish Orphan Biovitrum AB Chairman of the Board Hakan Bjorklund will not be available..
AQ
More news
Financials
Sales 2022 18 213 M 1 754 M 1 754 M
Net income 2022 2 448 M 236 M 236 M
Net Debt 2022 7 062 M 680 M 680 M
P/E ratio 2022 27,4x
Yield 2022 -
Capitalization 66 628 M 6 417 M 6 417 M
EV / Sales 2022 4,05x
EV / Sales 2023 3,63x
Nbr of Employees 1 555
Free-Float 57,8%
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 225,10 SEK
Average target price 250,60 SEK
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Hňkan Bj÷rklund Chairman
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Christine Wesstr÷m Head-Technical Operations
Sector and Competitors